Yu Wang, Ipsita Mukherjee, Arundhathi Venkatasubramaniam, Dustin Dikeman, Nicholas Orlando, Jing Zhang, Roger Ortines, Mark Mednikov, Shardulendra P Sherchand, Tulasikumari Kanipakala, Thao Le, Sanjay Shukla, Mark Ketner, Rajan P Adhikari, Hatice Karauzum, M Javad Aman, Nathan K Archer
Staphylococcus aureus is the leading cause of skin and soft tissue infections (SSTIs) in the U.S. as well as more serious invasive diseases, including bacteremia, sepsis, endocarditis, surgical site infections, osteomyelitis, and pneumonia. These infections are exacerbated by the emergence of antibiotic-resistant clinical isolates such as methicillin-resistant S. aureus (MRSA), highlighting the need for alternatives to antibiotics to treat bacterial infections. We have previously developed a multi-component toxoid vaccine (IBT-V02) in a liquid formulation with efficacy against multiple strains of Staphylococcus aureus prevalent in the industrialized world...
2024: Frontiers in Immunology